Viewing Study NCT03274492


Ignite Creation Date: 2025-12-24 @ 3:51 PM
Ignite Modification Date: 2026-01-25 @ 7:40 AM
Study NCT ID: NCT03274492
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-09-25
First Post: 2017-09-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Sponsor: Hoffmann-La Roche
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module